SL-325 study for people with Crohn's disease
Part of Digestive system clinical trials.
This study tests a new medicine called SL-325, which may help reduce inflammation in the gut. It is for people with moderate to severe Crohn's disease who have not responded well to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Crohn's disease for at least 3 months.
- Your Crohn's disease is moderate to severe, as shown by scores on standard tests.
- You have tried at least one other treatment (like steroids, immune system drugs, or biologics) and it did not work well enough or you could not tolerate it.
- You do not have certain other bowel conditions or complications like abscesses, strictures, or short bowel syndrome.
- You have not had more than two bowel surgeries or any surgery in the last 3 months.
- You have not taken medicines that target DR3 or TL1A proteins before.
- You do not have active tuberculosis or untreated latent tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new, gentler way to diagnose Crohn's disease. If you have symptoms like long-lasting diarrhea or belly pain, this study may help find out if you have Crohn's without invasive procedures.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.